11:57 AM
 | 
Nov 03, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Rgenix reports Phase I data for cancer compound RGX-104

Rgenix Inc. (New York, N.Y.) reported preliminary data from a Phase Ia/Ib trial showing that oral RGX-104 led to 4 cases of stable disease among 12 evaluable patients with advanced solid malignancies and lymphoma. RGX-104 increased activated circulating PD-1+ CD8+ T cells by up to 11-fold in 9 of 10 evaluable patients....

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >